Cautionary Note on the Use of Empiric Ceftriaxone for Suspected Bacteremia
Ellen R. Wald
Abstract
Ellen R. Wald
Abstract
Empiric use of parenteral ceftriaxone sodium is becoming increasingly prevalent in the treatment of suspected occult bacteremia in young, highly febrile children who lack an apparent focal infection other than presumed viral upper respiratory tract infection. This strategy has begun to pervade clinical practice in the absence of any published data to prove its efficacy. The authors of two recent exercises in decision analysis conclude that empiric antimicrobial therapy is the most cost-effective and clinically beneficial treatment startegy and recommend its use. 1,2 We write to express concern and urge caution in adopting this approach lest it further complicate the difficult task of treating occult bacteremia by requiring a more extensive evaluation and generating a potentially ambiguous database. Occult bacteremia is a relatively common problem in pediatric patients, occurring most often in children between ages 3 and 36 months with temperatures of at least 38.9°C. Numerous reports have identified an
OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Empiric use of parenteral ceftriaxone sodium is becoming increasingly prevalent in the treatment of suspected occult bacteremia in young, highly febrile children who lack an apparent focal infection other than presumed viral upper respiratory tract infection. This strategy has begun to pervade clinical practice in the absence of any published data to prove its efficacy. The authors of two recent exercises in decision analysis conclude that empiric antimicrobial therapy is the most cost-effective and clinically beneficial treatment startegy and recommend its use. 1,2 We write to express concern and urge caution in adopting this approach lest it further complicate the difficult task of treating occult bacteremia by requiring a more extensive evaluation and generating a potentially ambiguous database. Occult bacteremia is a relatively common problem in pediatric patients, occurring most often in children between ages 3 and 36 months with temperatures of at least 38.9°C. Numerous reports have identified an
Key concepts: Ceftriaxone, Bacteremia, Medicine, Empiric therapy, Intensive care medicine, Antibiotics, Microbiology, Biology